(VIANEWS) – Bristol (BMY), BlackRock (BLK), Northrim BanCorp (NRIM) are the highest payout ratio stocks on this list.
We have collected information regarding stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Bristol (BMY)
64.72% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
In addition to the exclusive U.S. license optioned in June 2021, Bristol Myers Squibb will now be responsible for the development, manufacturing and commercialization of PRX005., Under the terms of the deal, Bristol Myers Squibb will pay $55 million to Prothena for the worldwide license to PRX005.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.43.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 18.2. Meaning, the purchaser of the share is investing $18.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.07%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4.7% and 0.5%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Bristol’s EBITDA is 33.31.
Previous days news about Bristol (BMY)
- According to Zacks on Tuesday, 11 July, "Prothena Corporation plc (PRTA Quick QuotePRTA – Free Report) has announced a significant milestone in its collaboration with Bristol Myers Squibb (BMY Quick QuoteBMY – Free Report) .", "The partnership has resulted in Bristol Myers Squibb exercising its option to obtain exclusive worldwide commercial rights for PRX005, Prothena’s groundbreaking anti-tau antibody designed for the potential treatment of Alzheimer’s disease."
- According to Zacks on Tuesday, 11 July, "Opdivo and Yervoy are two of the many blockbuster drugs marketed by Bristol Myers. ", "During first-quarter 2023, Bristol Myers generated $2.2 billion from Opdivo sales and recorded $508 million as product revenues from Yervoy."
- Bristol myers (bmy) reports positive data from urothelial cancer study. According to Zacks on Wednesday, 12 July, "Shares of Bristol Myers have fallen 12.8% year to date compared with the industry’s 10.6% decline.", "Bristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote"
2. BlackRock (BLK)
60.88% Payout Ratio
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks. It also provides global risk management and advisory services. The firm manages separate client-focused equity, fixed income, and balanced portfolios. It also launches and manages open-end and closed-end mutual funds, offshore funds, unit trusts, and alternative investment vehicles including structured funds. The firm launches equity, fixed income, balanced, and real estate mutual funds. It also launches equity, fixed income, balanced, currency, commodity, and multi-asset exchange traded funds. The firm also launches and manages hedge funds. It invests in the public equity, fixed income, real estate, currency, commodity, and alternative markets across the globe. The firm primarily invests in growth and value stocks of small-cap, mid-cap, SMID-cap, large-cap, and multi-cap companies. It also invests in dividend-paying equity securities. The firm invests in investment grade municipal securities, government securities including securities issued or guaranteed by a government or a government agency or instrumentality, corporate bonds, and asset-backed and mortgage-backed securities. It employs fundamental and quantitative analysis with a focus on bottom-up and top-down approach to make its investments. The firm employs liquidity, asset allocation, balanced, real estate, and alternative strategies to make its investments. In real estate sector, it seeks to invest in Poland and Germany. The firm benchmarks the performance of its portfolios against various S&P, Russell, Barclays, MSCI, Citigroup, and Merrill Lynch indices. BlackRock, Inc. was founded in 1988 and is based in New York City with additional offices in Boston, Massachusetts; London, United Kingdom; Gurgaon, India; Hong Kong; Greenwich, Connecticut; Princeton, New Jersey; Edinburgh, United Kingdom; Sydney, Australia; Taipei, Taiwan; Singapore; Sao Paulo, Brazil; Philadelphia, Pennsylvania; Washington, District of Columbia; Toronto, Canada; Wilmington, Delaware; and San Francisco, California.
Earnings Per Share
As for profitability, BlackRock has a trailing twelve months EPS of $32.23.
PE Ratio
BlackRock has a trailing twelve months price to earnings ratio of 22.71. Meaning, the purchaser of the share is investing $22.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.32%.
Yearly Top and Bottom Value
BlackRock’s stock is valued at $732.08 at 14:23 EST, under its 52-week high of $785.65 and way above its 52-week low of $503.12.
Previous days news about BlackRock (BLK)
- According to Zacks on Tuesday, 11 July, "Eight institutions have filed papers for a Bitcoin ETF in the past few months, including Fidelity and the world’s largest asset manager, BlackRock ((BLK Quick QuoteBLK – Free Report) ). "
- According to MarketWatch on Tuesday, 11 July, "Helping fuel recent investor interest in Coinbase, as well as in bitcoin, BlackRock Inc. and several other asset managers recently edged up 0.4% on Tuesday, but has slipped 0.5% month to date."
3. Northrim BanCorp (NRIM)
40.94% Payout Ratio
Northrim BanCorp, Inc. operates as the bank holding company for Northrim Bank that provides commercial banking products and services to businesses and professional individuals. It operates in two segments, Community Banking and Home Mortgage Lending. The company offers noninterest-bearing checking accounts and interest-bearing time deposits, checking and savings accounts, individual retirement accounts, money market deposit accounts, and certificates of deposit. It also provides family residential mortgages; commercial loans, such as secured and unsecured loans for working capital and expansion; commercial real estate loans; construction loans for commercial real estate projects, and land development and residential subdivision construction loans; and loans for automobiles, recreational vehicles, boats, and other consumer purchases, as well as home equity and commercial credit lines, and factoring services. In addition, the company offers other services that include consumer online banking, mobile app and mobile deposit, mobile Web and text banking, business online banking, personal finance, online documents, consumer and business debit cards, home equity advantage access cards, and telebanking and automated teller services. Further, it provides personalized checks, overdraft protection from savings accounts, commercial drive-up banking, automatic transfers and payments, people pay, external and wire transfers, bill pay, direct payroll deposits, electronic tax payments, automated clearing house origination and receipt, remote deposit capture, and account reconciliation and positive pay services, as well as merchant and cash management programs, annuity products, and long term investment portfolios. As of December 31, 2020, the company operated 16 branches in Anchorage, the Matanuska-Susitna Valley, Juneau, Fairbanks, Ketchikan, Sitka, and Kenai Peninsula. Northrim BanCorp, Inc. was founded in 1990 and is headquartered in Anchorage, Alaska.
Earnings Per Share
As for profitability, Northrim BanCorp has a trailing twelve months EPS of $4.93.
PE Ratio
Northrim BanCorp has a trailing twelve months price to earnings ratio of 7.98. Meaning, the purchaser of the share is investing $7.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.59%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 68.7% and a drop 8.5% for the next.
Yearly Top and Bottom Value
Northrim BanCorp’s stock is valued at $39.33 at 14:23 EST, way under its 52-week high of $56.77 and way higher than its 52-week low of $33.29.
4. Pfizer (PFE)
31.76% Payout Ratio
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Caribou Up on Pfizer Investment: Shares of leading CRISPR genome-editing biopharmaceutical company, Caribou Biosciences, Inc., (CRBU Quick QuoteCRBU – Free Report) , surged after it received an equity investment from pharma giant Pfizer. , Per the terms, Pfizer has purchased 4,690,431 common shares of Caribou for $5.33 per share, resulting in a $25 million equity investment.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $5.07.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 7.13. Meaning, the purchaser of the share is investing $7.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.62%.
Previous days news about Pfizer (PFE)
- Pfizer just invested $25 million in this biotech. According to FXStreet on Tuesday, 11 July, "The move by Pfizer certainly shows confidence in Caribou’s management team and pipeline. ", "The investment by Pfizer signals a strong confidence in Caribou’s pipeline and lead candidates."
- According to Zacks on Wednesday, 12 July, "Other key players in the GLP-1 market include pharma bigwigs like Eli Lilly (LLY Quick QuoteLLY – Free Report) and Pfizer (PFE Quick QuotePFE – Free Report) .", "In May 2023, Pfizer reported positive data from the phase II study of its oral type II diabetes candidate, danuglipron. "
